

EXHIBIT 1

1) Spleen

Donor: BALB/c ♀

Age at 1st injection: 12 weeks

Immunogen: NTC + 10-12h P₂A₃₃₃

	Date	Cell#	application	adjuvant	FACS-result	comments
Injections:		b.c. 9951			87% CD69	
		↳ NTC		no	95% OKT3 (6h)	
		5 · 10 ⁶	i.p.		64% TRAP	
		"	i.p.	no	83% OKT3 ⁺ ; 47% TRAP ⁺ (12h)	
		9951	i.p.		94% OKT3 ⁺ ; 66% TRAP ⁺ (12h)	
		b.c. 9951	i.p.			
		↳ 889	i.p.			
		↳ NTC	i.p.			
		10 ⁷ 889	i.p.			

spleen cell#

2) Myeloma

Cell line: P3X63 Ag8.653

Density:

% dead

Medium: R10F⁻ (H)

Thawed aliquot from:

3) Fusion

Myeloma / spleen cell ratio:

Fusion medium:

PEG lot:

Protocol:

4) Selection

Percent of fusion seeded:

Density seeded:

U96 (F96)

Selection medium:

Serum lot:

Azaserin/Hyp. lot:

Aza final:

Hyp. final:

First hybridomas grow:

Myeloma-spleen-fusion

No.: Ba-1 [A]

Date:

1) Spleen

Donor: BALB/C ♀

Age at 1st injection: 12 Weeks

Immunogen: NTC + 10-12 h P_{20A333}

[D]	Date	Cell#	application	adjuvant	FACS-result	comments
Injections:		bc9951			87% CD69	
	↳ NTC				95% OKT3 (6 h)	
	5x10 ⁶		i.p.	no	64% TRAP	
	:	"	i.p.	no	89% OKT3 ⁺ ; 47% TRAP ⁺ (12 h)	
		bc9951	i.p.	"	94% OKT3 ⁺ ; 66% TRAP ⁺ (12 h)	
		889	i.p.	"		
	↳ NTC					
		10 ⁷ 889	i.p.	"		

spleen cell#

2) Myeloma

Cell line: P3X63Ag8.653

Density

%dead

Medium: R10F⁺ H

Thawed aliquot from:

3) Fusion

Myeloma/spleen cell ration:

Fusion medium:

PEG lot:

Protocol:

4) Selection

Percent of fusion seeded

Density seeded:

U96/F96 [H]

Selection medium:

Serum lot:

Azaserin/Hyp. lot:

Aza final:

Hyp. final:

First hybridomas grow